We Think PharmaResearch's (KOSDAQ:214450) Healthy Earnings Might Be Conservative

The stock was sluggish on the back of PharmaResearch Co., Ltd.'s (KOSDAQ:214450) recent earnings report. We have done some analysis, and found some encouraging factors that we believe the shareholders should consider.

earnings-and-revenue-history
KOSDAQ:A214450 Earnings and Revenue History March 24th 2025
Advertisement

How Do Unusual Items Influence Profit?

To properly understand PharmaResearch's profit results, we need to consider the ₩15b expense attributed to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. If PharmaResearch doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On PharmaResearch's Profit Performance

Because unusual items detracted from PharmaResearch's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think PharmaResearch's earnings potential is at least as good as it seems, and maybe even better! Better yet, its EPS are growing strongly, which is nice to see. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. Obviously, we love to consider the historical data to inform our opinion of a company. But it can be really valuable to consider what other analysts are forecasting. Luckily, you can check out what analysts are forecasting by clicking here.

Today we've zoomed in on a single data point to better understand the nature of PharmaResearch's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About KOSDAQ:A214450

PharmaResearch

Operates as a biopharmaceutical company primarily in South Korea.

Outstanding track record and undervalued.

Advertisement

Weekly Picks

DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.887.9% undervalued
18 users have followed this narrative
1 users have commented on this narrative
13 users have liked this narrative
TO
Tokyo
MC logo
Tokyo on LVMH Moët Hennessy - Louis Vuitton Société Européenne ·

EU#4 - Turning Heritage into the World’s Strongest Luxury Empire

Fair Value:€750.0429.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
GOOGL logo
WealthAP on Alphabet ·

The "Easy Money" Is Gone: Why Alphabet Is Now a "Show Me" Story

Fair Value:US$386.4312.1% undervalued
57 users have followed this narrative
1 users have commented on this narrative
15 users have liked this narrative

Updated Narratives

FH
SOF logo
fhuyge on Sofina Société Anonyme ·

Why I invest in Sofina (Dividend growth)

Fair Value:€332.3828.6% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ID
VNOM logo
Idle on Viper Energy ·

Great dividend but share numbers have increased 100% in last 12 months!!

Fair Value:US$32.9926.9% overvalued
10 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RE
PROX logo
RecMag on Proximus ·

Proximus: The State-Backed Backup Plan with 7% Gross Yield and 15% Currency Upside.

Fair Value:€17.1354.8% undervalued
37 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

WE
WealthAP
PYPL logo
WealthAP on PayPal Holdings ·

The "Sleeping Giant" Stumbles, Then Wakes Up

Fair Value:US$8249.1% undervalued
85 users have followed this narrative
6 users have commented on this narrative
35 users have liked this narrative
OO
NEO logo
OOO97 on Neo Performance Materials ·

Undervalued Key Player in Magnets/Rare Earth

Fair Value:CA$25.3320.9% undervalued
75 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0228.7% undervalued
1050 users have followed this narrative
6 users have commented on this narrative
31 users have liked this narrative

Trending Discussion

HE
Hemingway
AEVA logo
Hemingway on Aeva Technologies ·

NVDA+AEVA Agreement is a game changer for the AEVA stock even though it is just a partnership and does not have a roll out until 2028 (which means receivables as early as 2027, I would imagine) This agreement effectively moves the goal posts of profitability for AEVA much closer since this is in addition to the recent Forterra agreement, as well as the (previously announced) European carmaker agreement (which is believed to be Mercedes-Benz and estimated to be worth at least 1 billion in sales alone) Underneath all of this, AEVA has a pre-existing agreement with Daimler Truck. So business seems to be booming, especially with really big name brands…which tends to bring in even more brand names (and thus more agreements/contracts/announcements, etc). This dynamic often creates more coverage from analysts (often with upside stock initial coverage) that I believe will be occurring over the next 3 to 6 months (as professional traders/analysts often research for 2 to 3 months before initiating coverage of a new issue). I also feel that the above momentum increases the likelihood that companies that do not currently utilize 4G LIDAR technology might consider buying AEVA outright. Realistically, even with a substantial premium to the current stock price, the cost of AEVA would be a rounding error for the likes of a company such as Tesla, and certainly would allow them to maintain their technological edge as the competition for self-driving vehicles continues to heat up. However, I think it is equally possible for NVidea to decide to lock-in the AEVA technology for their upcoming autonomous hardware/software package by buying them outright. Obviously, the above factors and recent activity in the AEVA stock are cause for optimism. Of course, this all just one opinion , so please do your own due diligence. Disclaimer: I/We DO trade in this stock from time to time and I/we may (or may not have) a position currently, so again, please do your own due diligence.

0
|
0
US
AVGO logo
User on Broadcom ·

Net here,remains to be seen!

0
|
0
Advertisement